Published in J Clin Oncol on December 19, 2005
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | NCT00868192
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol (2015) 3.24
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol (2008) 2.18
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer (2006) 2.11
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer (2008) 2.09
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol (2008) 1.61
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer (2010) 1.42
CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res (2008) 1.33
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol (2009) 1.27
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer (2009) 1.22
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis (2009) 1.20
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol (2010) 1.19
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol (2010) 1.17
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A. CPT Pharmacometrics Syst Pharmacol (2016) 1.12
Antiangiogenic therapy for cancer: an update. Pharmacotherapy (2012) 1.10
Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer (2009) 1.09
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol (2012) 1.09
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer (2013) 1.08
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis (2010) 1.07
Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol (2009) 1.04
Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci (2011) 1.01
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol (2012) 0.99
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol (2011) 0.97
Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 0.96
Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther (2012) 0.95
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer (2011) 0.94
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol (2010) 0.92
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer (2011) 0.91
Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal (2014) 0.90
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med (2008) 0.90
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol (2007) 0.88
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer (2009) 0.87
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br J Cancer (2012) 0.87
Transcriptome sequencing reveals differences between primary and secondary hair follicle-derived dermal papilla cells of the Cashmere goat (Capra hircus). PLoS One (2013) 0.87
Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol (2007) 0.86
Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer (2006) 0.86
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol (2011) 0.85
Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res (2013) 0.84
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer (2013) 0.83
The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. Dig Dis Sci (2008) 0.82
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Invest New Drugs (2012) 0.82
Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst (2013) 0.82
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer (2015) 0.81
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer (2013) 0.81
Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res (2007) 0.81
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol (2015) 0.81
Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. Biologics (2007) 0.80
Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics (2008) 0.80
The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med (2014) 0.80
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) (2010) 0.80
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) (2014) 0.80
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer (2015) 0.79
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79
Endometrial cancer. Obstet Gynecol Clin North Am (2012) 0.79
Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol (2009) 0.79
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol (2012) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. Br J Cancer (2015) 0.78
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother (2013) 0.78
Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case Rep Oncol (2009) 0.78
A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep (2015) 0.78
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol (2015) 0.78
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol (2015) 0.78
Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol (2016) 0.77
Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. Am J Cancer Res (2015) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal. Clin Cancer Res (2013) 0.77
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther (2015) 0.76
Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment? Med Sci Monit (2014) 0.76
Biomarkers of Angiogenesis in Colorectal Cancer. Biomark Cancer (2015) 0.76
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? Clin Med Insights Oncol (2016) 0.76
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience (2015) 0.76
Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue. PLoS One (2016) 0.75
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer (2015) 0.75
Blood-based biomarkers for the optimization of anti-angiogenic therapies. Cancers (Basel) (2010) 0.75
Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci (2014) 0.75
When does the presence of the target predict response to the targeted agent? J Clin Oncol (2005) 0.75
A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol (2005) 4.32
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 2.23
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res (2007) 1.90
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 1.78
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Expression profiling the human septin gene family. J Pathol (2005) 1.67
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology (2010) 1.62
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 1.55
WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol (2004) 1.53
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Towards establishment of a rice stress response interactome. PLoS Genet (2011) 1.47
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 1.44
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. Mol Cell Biol (2005) 1.39
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res (2004) 1.35
Neuropilin-1 expression in cancer and development. J Pathol (2011) 1.34
Overexpression of the endoplasmic reticulum chaperone BiP3 regulates XA21-mediated innate immunity in rice. PLoS One (2010) 1.32
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res (2006) 1.29
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28
In situ validation of an intestinal stem cell signature in colorectal cancer. Gut (2012) 1.26
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res (2004) 1.25
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol (2007) 1.25
Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells. J Biol Chem (2003) 1.25
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Lung deposition and extrapulmonary translocation of nano-ceria after intratracheal instillation. Nanotechnology (2010) 1.24
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res (2010) 1.23
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol (2006) 1.20
Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med (2004) 1.20
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist (2013) 1.19
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg (2007) 1.19
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB (2009) 1.18